Population Pharmacokinetics of Imatinib in CML Patients in Iran

Kerman University of Medical Sciences

Status: Terminated

Conditions: Chronic Myelogenous Leukemia

Treatments: Drug: Imatinib

Study type: Observational

Funder types: Other

Identifiers

NCT02146846

Kerman-001-FOPPT

Details and patient eligibility

About

The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.

Full description

patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study then population pharmacokinetics parameters is determined.

Enrollment: 170 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient in chronic phase of myeloid leukemia
• no liver and renal failure

Exclusion criteria

• multiple dug treatment
• previous treatment of interferon
• patients in blast or accelerated phase

Trial design

170 participants in 1 patient group

Imatinib, CML

Description:

Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study

Treatment:

Drug: Imatinib